Sagimet Biosciences Inc [SGMT] stock is trading at $4.31, up 4.11%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SGMT shares have gain 5.38% over the last week, with a monthly amount glided 26.76%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Sagimet Biosciences Inc [NASDAQ: SGMT] stock has seen the most recent analyst activity on June 28, 2024, when Goldman downgraded its rating to a Neutral and also revised its price target to $6 from $23. Previously, H.C. Wainwright started tracking the stock with Buy rating on May 02, 2024, and set its price target to $32. On March 25, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $26 on the stock. TD Cowen started tracking the stock assigning a Outperform rating. Piper Sandler initiated its recommendation with a Overweight and recommended $67 as its price target on August 08, 2023. JMP Securities started tracking with a Mkt Outperform rating for this stock on August 08, 2023, and assigned it a price target of $30. In a note dated August 08, 2023, Goldman initiated an Buy rating and provided a target price of $33 on this stock.
Sagimet Biosciences Inc [SGMT] stock has fluctuated between $2.13 and $20.71 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Sagimet Biosciences Inc [NASDAQ: SGMT] shares were valued at $4.31 at the most recent close of the market. An investor can expect a potential return of 39.21% based on the average SGMT price forecast.
Analyzing the SGMT fundamentals
Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -18.14%, Pretax Profit Margin comes in at -14.63%, and Net Profit Margin reading is -14.63%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.21 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.09 points at the first support level, and at 3.86 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.48, and for the 2nd resistance point, it is at 4.64.
Ratios To Look Out For
For context, Sagimet Biosciences Inc’s Current Ratio is 29.11. In addition, the Quick Ratio stands at 29.11 and the Cash Ratio stands at 16.75. Considering the valuation of this stock, the price to sales ratio is 69.39, the price to book ratio is 0.75.
Transactions by insiders
Recent insider trading involved Kemble George, Executive Chairman, that happened on Jul 23 ’24 when 23625.0 shares were sold. Chief Medical Officer, Martins Eduardo Bruno completed a deal on Jul 19 ’24 to sell 8357.0 shares. Meanwhile, General Counsel and CCO Rozek Elizabeth sold 10914.0 shares on Jul 19 ’24.
